Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China.
Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China.
Br J Radiol. 2024 Mar 28;97(1156):859-867. doi: 10.1093/bjr/tqae025.
As a promising positron emission tomography (PET) tracer, [68Ga]Ga-fibroblast activation protein inhibitor-04([68Ga]Ga-FAPI-04) performs better than 2-[18F]fluoro-2-deoxy-d-glucose ([18F]FDG) at diagnosing primary and metastatic lesions in patients with various types of cancer. We investigated the utility of [68Ga]Ga-FAPI-04 PET/CT for the detection of primary and metastatic lesions in renal cell carcinoma (RCC). [18F]FDG PET/CT were used for comparison.
Twenty-two patients with suspected RCC or recurrent RCC were enrolled in our study. Among these patients, 14 were newly diagnosed with RCC, 3 had recurrent RCC, and 5 were excluded from further analysis due to having benign renal tumours. Seventeen patients with RCC underwent [68Ga]Ga-FAPI-04 PET/CT, and 6 of them also received [18F]FDG PET/CT. The positive detection rates were calculated and compared with those in patients who underwent both scans.
Data from 17 patients with RCC (median age: 60.5 years, interquartile range [IQR]: 54-70 years) were evaluated. The positive detection rate of [68Ga]Ga-FAPI-04 PET/CT for RCC was 64.7% (11/17). Lymph node metastases (n = 44), lung metastasis (n = 1), and bone metastasis (n = 1) were detected. Six patients with RCC underwent [68Ga]Ga-FAPI-04 and [18F]FDG PET/CT. [68Ga]Ga-FAPI-04 PET/CT showed a higher positive detection rate than [18F]FDG PET/CT in detecting RCC (83.3% [5/6] vs. 50% [3/6], P = 0.545). Additionally, [68Ga]Ga-FAPI-04 PET/CT has higher SUVmax (3.20 [IQR: 2.91-5.80 vs. 2.71 [IQR: 2.13-3.10], P = 0.116) and tumour-to-background ratio (TBR) values (1.60 [IQR: 1.33-3.67] vs. 0.86 [0.48-1.21], P = 0.028) than [18F]FDG PET/CT.
These findings suggest that [68Ga]Ga-FAPI-04 PET/CT has potential value in RCC diagnosis. Further studies are warranted to validate these results.
Clinical utility of [68Ga]Ga-FAPI-04 in RCC remains unclear, and there are not many similar studies in the literature. We evaluated the role of [68Ga]Ga-FAPI-04 in diagnosing RCC.
作为一种有前途的正电子发射断层扫描（PET）示踪剂，[68Ga]镓-成纤维细胞激活蛋白抑制剂-04([68Ga]Ga-FAPI-04) 在诊断各种类型癌症患者的原发性和转移性病变方面优于 2-[18F]氟-2-脱氧-d-葡萄糖([18F]FDG)。我们研究了[68Ga]Ga-FAPI-04 PET/CT 在肾细胞癌（RCC）中的应用。[18F]FDG PET/CT 用于比较。
22 例疑似 RCC 或复发性 RCC 的患者纳入本研究。其中，14 例为初诊 RCC，3 例为复发性 RCC，5 例因良性肾肿瘤而被排除进一步分析。17 例 RCC 患者接受了[68Ga]Ga-FAPI-04 PET/CT 检查，其中 6 例还接受了[18F]FDG PET/CT 检查。计算阳性检出率，并与接受两种扫描的患者进行比较。
对 17 例 RCC 患者（中位年龄：60.5 岁，四分位距[IQR]：54-70 岁）的数据进行了评估。[68Ga]Ga-FAPI-04 PET/CT 对 RCC 的阳性检出率为 64.7%（11/17）。检测到淋巴结转移（n=44）、肺转移（n=1）和骨转移（n=1）。6 例 RCC 患者接受了[68Ga]Ga-FAPI-04 和[18F]FDG PET/CT。[68Ga]Ga-FAPI-04 PET/CT 比[18F]FDG PET/CT 在检测 RCC 方面具有更高的阳性检出率（83.3%[5/6] vs. 50%[3/6]，P=0.545）。此外，[68Ga]Ga-FAPI-04 PET/CT 的 SUVmax（3.20[IQR：2.91-5.80] vs. 2.71[IQR：2.13-3.10]，P=0.116）和肿瘤与背景比（TBR）值（1.60[IQR：1.33-3.67] vs. 0.86[0.48-1.21]，P=0.028）均高于[18F]FDG PET/CT。
这些发现表明[68Ga]Ga-FAPI-04 PET/CT 在 RCC 诊断中具有潜在价值。需要进一步的研究来验证这些结果。
[68Ga]Ga-FAPI-04 在 RCC 中的临床应用尚不清楚，文献中也没有很多类似的研究。我们评估了[68Ga]Ga-FAPI-04 在诊断 RCC 中的作用。
